Caplin Point Lab

Who are the top shareholders of the Caplin Point Lab?

The top shareholders of Caplin Point Lab include promoter P Vijayalakshmi with 24.71%, 17 mutual fund schemes holding 1.74%, 139 foreign institutional investors with 5.73%, and individual investors owning 15.11%. The highest public shareholder is Uti Small Cap Fund at 1.27%.

The top shareholders of Caplin Point Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is P Vijayalakshmi, who owns 24.71% of the company. Additionally, there are 17 mutual fund schemes that collectively hold 1.74%, and 139 foreign institutional investors (FIIs) with a combined holding of 5.73%. The highest public shareholder is Uti Small Cap Fund, which holds 1.27%. Individual investors also have a significant presence, holding 15.11% of the shares.

What does Caplin Point Lab do?

Caplin Point Laboratories Ltd is a mid-cap pharmaceutical company that develops, produces, and markets generic and branded products. As of March 2025, it reported net sales of 502 Cr and a net profit of 143 Cr.

Overview: <BR>Caplin Point Laboratories Ltd is a fully integrated pharmaceutical company engaged in the production, development, and marketing of a wide range of generic formulations and branded products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Mid Cap.<BR><BR>History: <BR>Incorporated on April 16th, 1990, Caplin Point Laboratories has maintained its status as a fully integrated pharma company. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 502 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 143 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 15,957 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 30.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.26% <BR>Debt Equity: -0.31 <BR>Return on Equity: 18.81% <BR>Price to Book: 5.65<BR><BR>Contact Details: <BR>Address: Ashvich Towers 3rd Floor, No 3 Developed Plots Ind Estat Chennai Tamil Nadu : 600096 <BR>Tel: 91-44-24968000/71148000/28156653 <BR>Email: investor@caplinpoint.net/info@capli <BR>Website: http://www.caplinpoint.net

Has Caplin Point Lab declared dividend?

Yes, Caplin Point Laboratories Ltd has declared a 150% dividend, amounting to ₹3 per share, with an ex-date of May 30, 2025. The dividend yield is 0.26%, and the company has shown strong total returns over various periods.

Caplin Point Laboratories Ltd has declared a 150% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 150%<BR>- Amount per share: 3<BR>- Ex-date: May 30, 2025<BR><BR>Dividend Yield: 0.26%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -10.8%, the dividend return was 0.13%, resulting in a total return of -10.67%.<BR><BR>Over the past year, the price return was 60.93%, the dividend return was 0.38%, leading to a total return of 61.31%.<BR><BR>In the 2-year period, the price return was 170.89%, the dividend return was 1.29%, culminating in a total return of 172.18%.<BR><BR>For the 3-year period, the price return was 173.41%, with a dividend return of 2.11%, resulting in a total return of 175.52%.<BR><BR>In the last 4 years, the price return was 251.24%, the dividend return was 2.72%, giving a total return of 253.96%.<BR><BR>Finally, over the past 5 years, the price return was 540.68%, the dividend return was 5.90%, leading to a total return of 546.58%.<BR><BR>Overall, Caplin Point Laboratories Ltd has demonstrated significant total returns over various periods, with a notable dividend declaration, indicating a commitment to returning value to shareholders. The dividend yield, while modest, reflects a consistent approach to shareholder returns alongside strong price appreciation.

Who are the peers of the Caplin Point Lab?

Caplin Point Lab's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Blue Jet Health, Natco Pharma, Sai Life, Neuland Labs, and Sanofi India. Key insights show excellent management risk and growth for Sun Pharma, Cipla, and Dr Reddy's Labs, while Blue Jet Health leads in 1-year returns at 139.62%, and Natco Pharma has the lowest at -13.53%.

Peers: The peers of Caplin Point Lab are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Blue Jet Health, Natco Pharma, Sai Life, Neuland Labs, and Sanofi India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Blue Jet Health, Natco Pharma, and Neuland Labs, while Average management risk is found at Sai Life. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is noted for Divi's Lab., Torrent Pharma, and Blue Jet Health, and average growth is seen at Caplin Point Lab. Capital structure is excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Caplin Point Lab, Blue Jet Health, Natco Pharma, and Neuland Labs, while good capital structure is found at Torrent Pharma and Sai Life.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Blue Jet Health at 139.62%, while Natco Pharma has the lowest at -13.53%. Caplin Point Lab's 1-year return of 67.92% is significantly higher than Natco Pharma's. Additionally, the peers with negative six-month returns include Natco Pharma and Neuland Labs.

Is Caplin Point Lab overvalued or undervalued?

As of June 8, 2023, Caplin Point Lab is considered very expensive and overvalued with a PE ratio of 29.63 and an EV to EBITDA of 23.18, especially when compared to peers like Cipla and Sun Pharma, and has recently declined by 4.29% while the Sensex increased by 1.43%.

As of 8 June 2023, the valuation grade for Caplin Point Lab has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 29.63, an EV to EBITDA of 23.18, and a PEG ratio of 1.72, all suggesting a premium valuation compared to its earnings and growth potential.<BR><BR>In comparison with peers, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla presents a more attractive valuation with a PE of 22.99 and an EV to EBITDA of 15.93. The recent performance of Caplin Point Lab shows a 1-week decline of 4.29%, contrasting with a 1.43% increase in the Sensex, further reinforcing the notion of overvaluation in the current market environment.

Who are in the management team of Caplin Point Lab?

As of March 2023, the management team of Caplin Point Lab includes C C Paarthipan (Chairman), D Sathyanarayanan, C K Gariyali, Deenadayalan Singaram, R Nagendran (all Independent Directors), and Sridhar Ganesan (Non Independent Executive Director).

As of March 2023, the management team of Caplin Point Lab includes the following individuals:<BR><BR>1. C C Paarthipan - Chairman & Non Executive Director<BR>2. D Sathyanarayanan - Independent Non Executive Director<BR>3. C K Gariyali - Independent Director<BR>4. Deenadayalan Singaram - Independent Non Executive Director<BR>5. R Nagendran - Independent Non Executive Director<BR>6. Sridhar Ganesan - Non Independent Executive Director<BR><BR>These members play various roles within the company's governance and management structure.

How big is Caplin Point Lab?

As of 24th July, Caplin Point Laboratories Ltd has a market capitalization of 16,101.00 Cr, with recent net sales of 1,937.47 Cr and a net profit of 536.30 Cr. Shareholder's funds are 2,315.71 Cr, and total assets amount to 2,685.57 Cr.

As of 24th July, Caplin Point Laboratories Ltd has a market capitalization of 16,101.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,937.47 Cr and a Net Profit of 536.30 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 2,315.71 Cr and Total Assets of 2,685.57 Cr.

When is the next results date for Caplin Point Lab?

The next results date for Caplin Point Lab is 06 November 2025.

The next results date for Caplin Point Lab is scheduled for 06 November 2025.

How has been the historical performance of Caplin Point Lab?

Caplin Point Lab has shown consistent growth, with net sales increasing from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25, alongside improvements in operating profit, profit before tax, and total assets. Overall, the company's financial performance indicates a strong upward trend across key metrics.

Answer:<BR>The historical performance of Caplin Point Lab shows a consistent growth trajectory in key financial metrics over the years.<BR><BR>Breakdown:<BR>Caplin Point Lab has demonstrated significant growth in net sales, increasing from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25. This upward trend is reflected in total operating income, which also rose from 648.69 Cr in Mar'19 to 1,937.47 Cr in Mar'25. The company's operating profit (PBDIT) has similarly improved, reaching 743.36 Cr in Mar'25, up from 250.37 Cr in Mar'19. Profit before tax has followed suit, climbing from 226.88 Cr in Mar'19 to 676.79 Cr in Mar'25, while profit after tax increased from 176.56 Cr to 541.10 Cr over the same period. The company's total assets have expanded from 1,125.76 Cr in Mar'20 to 3,205.62 Cr in Mar'25, indicating robust asset growth. Shareholder's funds have also risen significantly, from 947.91 Cr in Mar'20 to 2,850.49 Cr in Mar'25. Cash flow from operating activities has improved, reaching 432.00 Cr in Mar'25, compared to 44.00 Cr in Mar'20, while net cash inflow turned positive at 60.00 Cr in Mar'25 after a negative outflow in the previous year. Overall, Caplin Point Lab's financial performance reflects a strong upward trend across various metrics, indicating a healthy and growing business.

Is Caplin Point Lab technically bullish or bearish?

As of November 27, 2025, Caplin Point Lab's technical trend has shifted to bearish, driven by negative indicators such as a bearish MACD and moving averages, despite some bullish signals in the monthly OBV.

As of 27 November 2025, the technical trend for Caplin Point Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. The Dow Theory also indicates a mildly bearish trend on the weekly and monthly time frames. Despite some bullish signals in the monthly OBV, the overall technical picture remains negative.

Are Caplin Point Laboratories Ltd latest results good or bad?

Caplin Point Laboratories Ltd's latest results show strong operational performance with a 18.08% increase in net profit and a 10.54% rise in revenue, but the stock has underperformed the market, declining 13.30% over the past year, which may warrant caution for potential investors.

Caplin Point Laboratories Ltd's latest results indicate a mixed performance. On the positive side, the company reported a net profit of ₹154.45 crores for Q2 FY26, which represents an 18.08% year-on-year increase, and revenue growth of 10.54% year-on-year, reaching ₹534.04 crores. Additionally, the operating margin improved to 35.42%, reflecting operational efficiency and a favorable product mix.<BR><BR>However, despite these solid fundamentals, the stock has underperformed the broader market, declining by 13.30% over the past year, which raises concerns about whether current valuations reflect the company's growth prospects adequately. The stock trades at a price-to-earnings (P/E) ratio of 24.59, which is below the sector average but still considered premium compared to some peers. <BR><BR>Overall, while the operational metrics show strength, the stock's underperformance and high valuation suggest caution for investors considering new positions.

Should I buy, sell or hold Caplin Point Laboratories Ltd?

Which are the latest news on Caplin Point Lab?

Why is Caplin Point Laboratories Ltd falling/rising?

As of 13-Mar, Caplin Point Laboratories Ltd's stock price is declining at 1,661.90, down 1.58%. This decline is due to a trend reversal, bearish moving averages, reduced investor participation, and concerns over its high valuation despite solid management efficiency.

As of 13-Mar, Caplin Point Laboratories Ltd is experiencing a decline in its stock price, currently at 1,661.90, which reflects a change of -26.7 or -1.58%. This drop can be attributed to several factors highlighted in the data. <BR><BR>Firstly, the stock has recently undergone a trend reversal, falling after five consecutive days of gains. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The intraday low reached was Rs 1654.15, marking a decrease of 2.04%. <BR><BR>Investor participation has also diminished, with a delivery volume of 30.63k on 12 March, which is down by 33.68% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors. <BR><BR>Despite the company showing high management efficiency with a return on equity (ROE) of 19.73% and a low debt-to-equity ratio, it has been deemed to have an expensive valuation with a price-to-book value of 4. Over the past year, while the company’s profits increased by 19.1%, the stock itself has underperformed the market, generating a return of -9.81% compared to the BSE500's positive return of 5.44%. <BR><BR>These factors collectively contribute to the stock's current downward movement, reflecting a combination of market sentiment and valuation concerns.

Why is Caplin Point Laboratories Ltd falling/rising?

As of 14-Mar, Caplin Point Laboratories Ltd's stock price is declining, currently at 1,661.90, following a trend reversal after five days of gains and trading below key moving averages. Despite strong management efficiency, the stock has underperformed the market over the past year, raising concerns about its valuation.

As of 14-Mar, Caplin Point Laboratories Ltd's stock price is falling, currently at 1,661.90, reflecting a decrease of 26.7 points or 1.58%. This decline follows a trend reversal after five consecutive days of gains. The stock has touched an intraday low of Rs 1654.15, marking a 2.04% drop. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>Investor participation has also decreased, with delivery volume dropping by 33.68% compared to the 5-day average, suggesting reduced interest among investors. Despite the company's strong management efficiency, highlighted by a high return on equity (ROE) of 19.73% and a low debt-to-equity ratio, the stock has underperformed the market significantly over the past year, generating a negative return of -9.81% while the broader market (BSE500) has returned 5.44%.<BR><BR>Furthermore, the stock is considered expensive with a price-to-book value of 4, and while profits have risen by 19.1%, the stock's performance has not reflected this growth, leading to concerns about its valuation. Overall, these factors contribute to the current decline in Caplin Point Laboratories Ltd's stock price.

Why is Caplin Point Laboratories Ltd falling/rising?

As of 15-Mar, Caplin Point Laboratories Ltd's stock price is falling to 1,661.90, down 1.58% after a trend reversal. The stock has underperformed in the short term and over the past year, with decreased investor interest and trading below key moving averages.

As of 15-Mar, Caplin Point Laboratories Ltd's stock price is falling, currently at 1,661.90, reflecting a decrease of 26.7 points or 1.58%. This decline follows a trend reversal after five consecutive days of gains. The stock has touched an intraday low of Rs 1654.15, which represents a drop of 2.04%. <BR><BR>The stock's performance has been underwhelming in the short term, with a 1-week change of -0.23% and a 1-month change of -4.09%. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Investor participation has also decreased, with delivery volume falling by 33.68% compared to the 5-day average, suggesting reduced interest in trading the stock.<BR><BR>Despite the company's strong management efficiency, evidenced by a high return on equity (ROE) of 19.73% and a low debt-to-equity ratio, the stock has underperformed the market significantly over the past year, generating a return of -9.81% while the broader market (BSE500) has returned 5.44%. This underperformance, coupled with a high valuation indicated by a price-to-book ratio of 4, has led to a perception of the stock as expensive compared to its peers, contributing to the current decline in its price.